Description: Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Home Page: rocketpharma.com
RCKT Technical Analysis
9 Cedarbrook Drive
Cranbury,
NJ
08512
United States
Phone:
609 659 8001
Officers
Name | Title |
---|---|
Dr. Gaurav D. Shah M.D. | CEO & Director |
Ms. Kinnari Patel M.B.A., MBA, Pharm.D., PharmD | Pres & COO |
Mr. Martin Louis Wilson J.D. | Gen. Counsel, Chief Compliance Officer & Sr. VP |
Mr. Jonathan Schwartz | Chief Medical Officer & Sr. VP of Clinical Devel. |
Mr. John C. Militello CPA, CPA | Interim Principal Financial Officer, VP, Sr. Controller, Treasurer & Principal Accounting Officer |
Mr. Mayo Pujols | Chief Technical Officer, Exec. VP & Director |
Mayur Kasetty M.B.A., M.D. | Bus. Devel. & Operations and Investor Relations Lead |
Ms. Jessie Yeung M.B.A. | VP of Investor Relations & Corp. Fin. |
Kevin Giordano | Director of Corp. Communications |
Ms. Isabel Carmona J.D. | Sr. VP & Chief HR Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 4.0724 |
Price-to-Sales TTM: | 0 |
IPO Date: | 2015-02-18 |
Fiscal Year End: | December |
Full Time Employees: | 151 |